ATORVASTATIN VS ROSUVASTATIN; FENOFIBRATE AS AN ADD ON: AN EXPLORATORY STUDY

Objective: Statins being the first choice drug for dyslipidaemia, the quest for better one among all has always been and still a question for research in the field of medicine. Objective ­ The objective of our study was to find out the best statin among the two, Atorvastatin and Rosuvastatin, in terms of efficacy and safety; alone or in combination with Fenofibrate for the management of dyslipidaemia. Methods: This was an open label, randomized, parallel group, prospective comparative study, carried out in patients in two groups treated with Atorvastatin and Rosuvastatin (10mg each) for 6 weeks, after which Fenofibrate (67mg) was added as an add on therapy in either group for the next 4 weeks before and after treatment. Results: After the treatment, the TC, TG, LDL- C, HDL- C and Non HDL- C were comparable between two groups. The changes in the levels of TC were -15.90±5.16 (-8.53%) vs -20.70±4.83 (-11.32%) respectively in groups treated with Atorvastatin (group I) and Rosuvastatin (group II). Changes in TGs were -11.60±4.16 (-7.46%) vs -15.10±5.18 (-9.99%), respectively; change in LDL- C were -16.90±3.58 (-15.31%) vs -13.0±3.04 (-11.56%) respectively; change in HDL- C were +6.75±0.86 (+18.72%) vs +9.0±1.22 (+23.72%) respectively in each group; change in Non HDL- C were found to be -6.90±4.83 (-4.4%) vs -7.8±4.78 (-5.05%) respectively in groups I and II. After the addition of Fenofibrate (67mg) there were no significant changes in the different parameters of serum lipid profile. Conclusion: The result of our study suggests that Rosuvastatin (10mg) was more efficacious than Atorvastatin (10mg) in lipid lowering effect and HDL- C raising effect but should be used with great caution and care in patients with uncontrolled hyperglycaemia and in those with compromised hepatic status. Further addition of Fenofibrate (67mg) didn’t make any significant difference in the result.